Oramed Pharmaceuticals (ORMP)
(Delayed Data from NSDQ)
$2.37 USD
+0.02 (0.85%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.38 +0.01 (0.42%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Oramed Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 162 | 156 | 146 | 94 | 40 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 1 |
Total Current Assets | 163 | 157 | 148 | 95 | 41 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 56 | 3 | 29 | 32 | 4 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 221 | 162 | 178 | 128 | 45 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 51 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 4 | 5 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 3 | 3 | 3 |
Total Current Liabilities | 53 | 6 | 7 | 7 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 4 | 3 | 4 | 7 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 58 | 10 | 11 | 11 | 12 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 321 | 314 | 293 | 230 | 125 |
Retained Earnings | -158 | -163 | -127 | -115 | -93 |
Other Equity | -1 | -1 | 0 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 163 | 151 | 167 | 117 | 33 |
Total Liabilities & Shareholder's Equity | 221 | 162 | 178 | 128 | 45 |
Total Common Equity | 163 | 151 | 167 | 117 | 33 |
Shares Outstanding | 40.30 | 39.10 | 38.20 | 26.60 | 17.70 |
Book Value Per Share | 4.04 | 3.87 | 4.36 | 4.38 | 1.86 |
Fiscal Year End for Oramed Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 162 | 175 | 150 | 154 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 1 | 1 |
Total Current Assets | NA | 163 | 176 | 151 | 155 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 56 | 53 | 4 | 3 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 221 | 231 | 156 | 160 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 51 | 75 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 1 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 1 |
Total Current Liabilities | NA | 53 | 78 | 1 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 4 | 4 | 4 | 4 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 58 | 83 | 6 | 10 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 321 | 320 | 319 | 317 |
Retained Earnings | NA | -158 | -171 | -168 | -166 |
Other Equity | NA | -1 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 163 | 148 | 151 | 150 |
Total Liabilities & Shareholder's Equity | NA | 221 | 231 | 156 | 160 |
Total Common Equity | 0 | 163 | 148 | 151 | 150 |
Shares Outstanding | 40.50 | 40.30 | 40.20 | 40.00 | 39.70 |
Book Value Per Share | 0.00 | 4.04 | 3.69 | 3.77 | 3.78 |